These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6622096)

  • 1. Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia.
    Kvittingen EA; Halvorsen S; Jellum E
    Pediatr Res; 1983 Jul; 17(7):541-4. PubMed ID: 6622096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts.
    Berger R; Van Faassen H; Taanman JW; De Vries H; Agsteribbe E
    Pediatr Res; 1987 Oct; 22(4):394-8. PubMed ID: 3317254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer.
    Phaneuf D; Hadchouel M; Tanguay RM; Bréchot C; Ferry N
    Biochem Biophys Res Commun; 1995 Mar; 208(3):957-63. PubMed ID: 7702626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein.
    Kvittingen EA; Rootwelt H; van Dam T; van Faassen H; Berger R
    Pediatr Res; 1992 Jan; 31(1):43-6. PubMed ID: 1594329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia.
    Kvittingen EA; Jellum E; Stokke O
    Clin Chim Acta; 1981 Sep; 115(3):311-9. PubMed ID: 7296877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase.
    Kvittingen EA; Brodtkorb E
    Scand J Clin Lab Invest Suppl; 1986; 184():35-40. PubMed ID: 3473612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.
    Kvittingen EA; Rootwelt H; Brandtzaeg P; Bergan A; Berger R
    J Clin Invest; 1993 Apr; 91(4):1816-21. PubMed ID: 8473520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme defect in a case of tyrosinemia type I, acute form.
    Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
    Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary tyrosinemia type I--an overview.
    Kvittingen EA
    Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.
    Berger R; Smit GP; Stoker-de Vries SA; Duran M; Ketting D; Wadman SK
    Clin Chim Acta; 1981 Jul; 114(1):37-44. PubMed ID: 7249373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes.
    Poudrier J; Lettre F; Scriver CR; Larochelle J; Tanguay RM
    Mol Genet Metab; 1998 Jun; 64(2):119-25. PubMed ID: 9705236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine and its catabolites: from disease to cancer.
    Tanguay RM; Jorquera R; Poudrier J; St-Louis M
    Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-induced correction of the genetic defect in tyrosinemia type I.
    Kvittingen EA; Rootwelt H; Berger R; Brandtzaeg P
    J Clin Invest; 1994 Oct; 94(4):1657-61. PubMed ID: 7929843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I).
    Tanguay RM; Valet JP; Lescault A; Duband JL; Laberge C; Lettre F; Plante M
    Am J Hum Genet; 1990 Aug; 47(2):308-16. PubMed ID: 2378356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.
    Grompe M; St-Louis M; Demers SI; al-Dhalimy M; Leclerc B; Tanguay RM
    N Engl J Med; 1994 Aug; 331(6):353-7. PubMed ID: 8028615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the enzymic defects in hereditary tyrosinemia.
    Lindblad B; Lindstedt S; Steen G
    Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4641-5. PubMed ID: 270706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.
    St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM
    Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency of fumarylacetoacetase without hereditary tyrosinemia.
    Kvittingen EA; Børresen AL; Stokke O; van der Hagen CB; Lie SO
    Clin Genet; 1985 Jun; 27(6):550-4. PubMed ID: 4017276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase.
    Nicole LM; Valet JP; Laberge C; Tanguay RM
    Biochem Cell Biol; 1986 May; 64(5):489-93. PubMed ID: 3718716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
    Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
    J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.